Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy
Open Access
- 15 July 2006
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 108 (2) , 452-459
- https://doi.org/10.1182/blood-2005-11-4570
Abstract
Antiangiogenic agents and therapeutic strategies have entered the clinical oncology arena. The classical tumor size measurements defined to monitor efficacy ofKeywords
This publication has 25 references indexed in Scilit:
- Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effectsAnnals of Oncology, 2005
- Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activityBlood, 2005
- Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic ActivityClinical Cancer Research, 2005
- Integrating Molecular Oncology Into Clinical Practice: Antiangiogenic TherapyJournal of Clinical Oncology, 2005
- A surrogate marker to monitor angiogenesis at lastCancer Cell, 2005
- Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesisCancer Cell, 2005
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levelsAnnals of Oncology, 2002